JHJohn P. Harrelson

John P. Harrelson

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


John P. Harrelson has a total of 38 co-authors. Here are the top co-authors by number of shared publications:

  • Sidney D. Nelson

    3 shared publications
  • Brendan David Stamper

    Pharmaceutical Sciences Department, Pacific University School of Pharmacy, United States

    2 shared publications
  • Aiden-Hung Nguyen

    Pacific Univ Sch of Pharmacy

    1 shared publication
  • Aleksandar Todorovic

    Chemistry Department, Pacific University Oregon, Forest Grove, Oregon (J.C., T.O., A.H., S.B.); and School of Pharmacy, Pacific University Oregon, Hillsboro, Oregon (S.T., A.H., S.B., A.T., F.E., J.P.H.).

    1 shared publication
  • Allyson Higa

    Chemistry Department, Pacific University Oregon, Forest Grove, Oregon (J.C., T.O., A.H., S.B.); and School of Pharmacy, Pacific University Oregon, Hillsboro, Oregon (S.T., A.H., S.B., A.T., F.E., J.P.H.).

    1 shared publication
  • Amber Virya King Buhler

    Pacific University School of Pharmacy, 222 SE 8th Ave., Suite 451, Hillsboro, OR 97123, United States

    1 shared publication

Latest Publications

  • Open Access

    In vitro and In vivo Inhibition of Nicotine Metabolism by trans-2-Nitrocinnamaldehyde

    by Aiden-Hung Nguyen, Uyen-Vy Navarro, Ghina Moyeen, John Harrelson

    ID 16923 Poster Board 181 Background: Pharmacogenomic studies show variation in nicotine metabolism influences smoking behaviors; slow metabolizers exhibit a decrease in smoking frequency. Thus, the design of inhibitors of nicotine metabolism is one approach for the discovery of new cessation therapies. Previous in vitro evidence demonstrate that trans-2-methoxycinnamaldehyde and trans-cinnamaldehyde are time-dependent inhibitors of human CYP2A6, the enzyme responsible for nicotine clearance. In vitro-to-in vivo extrapolation predicts a > 4-fold change in nicotine AUC (area under the curve). Here we evaluated the structural analog, trans-2-nitrocinnamaldehyde (NCA) in vitro, using human and mouse liver microsomes, and in vivo in C57GL/6J mice. Hypothesis: The addition of the nitro group will stabilize a purported terminal formyl radical and lead to greater in vitro and in vivo inhibition potency of nicotine metabolism. Methods: In vitro time-dependent inhibition studies were conducted by monitoring the remaining activity of nicotine metabolism after incubating NCA (0-120 μM) with human (2 mg/mL) and mouse liver microsomes (2 mg/mL) for 0 to 90 minutes. An aliquot was transferred to the secondary incubation system containing NADPH (1mM), nicotine (50 μM), and corresponding liver cytosol (1 mg/mL) at specific time points. After incubation for 15 minutes at 37 oC, each secondary incubation was quenched with ice-cold acetonitrile and the internal standard (D3-cotinine) was added. Cotinine was quantified using a Sciex 3500 LC-MS/MS. For in vivo studies, using adult male C57BL/6J mice, two modes of administration were selected. For oral administration, NCA was dissolved in the drinking water at the concentration of 0.088 mg/mL, to which the mice had access for three days prior to intraperitoneal injection of nicotine (1 mg/kg). To compare potency with methoxsalen (a known CYP2A6 inhibitor) NCA (57.1 mg/kg) was also administered via intraperitoneal injection. Blood was collected at specific time points (5 to 120 minutes). Samples were centrifuged to isolate plasma, D3-cotinine (internal standard) and acetonitrile were added, and then centrifuged. Supernatants were analyzed on LC-MS/MS to quantify nicotine and cotinine using standard curves generated in mouse plasma. Blood concentrations from four to five mice were measured for each time point and AUC values were estimated using Phoenix WinNonlin. Result: The in-vitro study using mouse liver microsomes showed that NCA time-dependently inhibited the formation of cotinine from nicotine with a kinact of 0.060 min-1 (± 0.024) and a KI of 6.0 μM (± 2.0). Oral administration of NCA in mice resulted in a nicotine plasma AUC of 355.9 ng*min/mL (geometric mean; 95% CI = 151.5 – 836.6), which is estimated to be 2.5 times higher than the control nicotine plasma AUC of 143.3 ng*min/mL (geometric mean; 95% CI: 112.2 – 183.0). Intraperitoneal injection of NCA and methoxsalen resulted in nicotine plasma AUC of 280.7 ng*min/mL (geometric mean; 95% CI =170.7 – 474.7; AUC-fold change = 1.96) and 957.6 ng*min/mL (geometric mean; 95% CI: 532.4 – 1665.8; AUC-fold change = 6.68), respectively. Conclusion: NCA is a more potent in vitro time-dependent inhibitor of nicotine metabolism compared to trans-2-methoxycinnamaldehyde and trans-cinnamaldehyde. Greater inhibition was observed with oral administration compared to intraperitoneal injection; this is evidence that NCA is reasonably stable in water to allow for oral dosing.

  • Mechanisms of Herb-Drug Interactions Involving Cinnamon and CYP2A6: Focus on Time-Dependent Inhibition by Cinnamaldehyde and 2-Methoxycinnamaldehyde

    by Michael J. Espiritu, Justin Chen, Jaydeep Yadav, Michael Larkin, Robert D. Pelletier, Jeannine M. Chan, Jeevan B. Gc, Senthil Natesan, John P. Harrelson

    Information is scarce regarding pharmacokinetic-based herb-drug interactions (HDI) with trans-cinnamaldehyde (CA) and 2-methoxycinnamaldehyde (MCA), components of cinnamon. Given the presence of cinnamon in food and herbal treatments for various diseases, HDIs involving the CYP2A6 substrates nicotine and letrozole with MCA (KS = 1.58 µM; Hill slope = 1.16) and CA were investigated. The time-dependent inhibition (TDI) by MCA and CA of CYP2A6-mediated nicotine metabolism is a complex process involving multiple mechanisms. Molecular dynamic simulations showed that CYP2A6’s active site accommodates two dynamic ligands. The preferred binding orientations for MCA and CA were consistent with the observed metabolism: epoxidation, O-demethylation, and aromatic hydroxylation of MCA and cinnamic acid formation from CA. The percent remaining activity plots for TDI by MCA and CA were curved, and they were analyzed with a numerical method using models of varying complexity. The best-fit models support multiple inactivator binding, inhibitor depletion, and partial inactivation. Deconvoluted mass spectra indicated that MCA and CA modified CYP2A6 apoprotein with mass additions of 156.79 (142.54–171.04) and 132.67 (123.37–141.98), respectively, and it was unaffected by glutathione. Heme degradation was observed in the presence of MCA (48.5% ± 13.4% loss; detected by liquid chromatography–tandem mass spectrometry). In the absence of clinical data, HDI predictions were made for nicotine and letrozole using inhibition parameters from the best-fit TDI models and parameters scaled from rats. Predicted area under the concentration-time curve fold changes were 4.29 (CA-nicotine), 4.92 (CA-letrozole), 4.35 (MCA-nicotine), and 5.00 (MCA-letrozole). These findings suggest that extensive exposure to cinnamon (corresponding to ≈ 275 mg CA) would lead to noteworthy interactions. Significance Statement Human exposure to cinnamon is common because of its presence in food and cinnamon-based herbal treatments. Little is known about the risk for cinnamaldehyde and methoxycinnamaldehyde, two components of cinnamon, to interact with drugs that are eliminated by CYP2A6-mediated metabolism. The interactions with CYP2A6 are complex, involving multiple-ligand binding, time-dependent inhibition of nicotine metabolism, heme degradation, and apoprotein modification. An herb-drug interaction prediction suggests that extensive exposure to cinnamon would lead to noteworthy interactions with nicotine.


  • Open Access

    Structure‐Toxicity Relationships of Trans‐Cinnamic Aldehyde and Its Substituted Analogs

    by Heather True, Chris Debusman, John Harrelson, Brendan Stamper

    Objective: Trans‐cinnamic aldehyde (CA) is a compound found in cinnamon and has promising potential as an agent for smoking cessation therapy. Current pharmaceutical options to treat nicotine addiction are only moderately effective and new approaches are needed. In this study, we aim to explore the hepatotoxicity profiles of CA and its structurally‐related analogs as one step in a more‐extensive evaluation of these agents to treat nicotine addiction. Methods: Mouse hepatocytes were exposed to varying concentrations of CA or its structurally‐related analogs and toxicity was measured by determining median lethal dose (LC50) values. Stock solutions for all compounds were prepared in DMSO and proper vehicle controls were performed for all experiments. Cells were treated with either CA or one of eight analogs: α‐bromocinnamaldehyde (Br‐CA), α‐chlorocinnamaldehyde (Cl‐CA), 3‐phenylpropionaldehyde (sat‐CA), α‐methylcinnamaldehyde (Me‐CA), 2‐nitrocinnamaldehyde (N‐CA), 2‐trifluoromethylcinnamadehyde (CF3‐CA), 2,6‐difluorocinnamaldehyde (F‐CA), and 2‐methylcinnamaldehyde (2‐Me‐CA). After the LC50 determinations were completed, two different luminescence‐based assays were performed to assess reactive oxygen species production and glutathione (GSH) depletion during exposure to CA and its analogs. A cutoff of p < 0.05 was used to determine significance by means of one‐way analysis of variance (ANOVA) with post‐hoc Least Significant Difference (LSD) tests. Results: Significant differences in LC50 values were observed across the tested compounds indicating minor structural changes to the structure of CA can have profound toxicologic effects. CA analogs modified to contain electron‐withdrawing groups, as well as CA itself, were generally more toxic (lower LC50 values) than those that did not contain electron‐withdrawing groups. Furthermore, this toxicity was associated with significantly greater reactive oxygen species production and GSH depletion compared to the other CA analogs at equi‐toxic doses. Conclusion: These results indicate analogs that contain electron‐withdrawing groups share a similar or inferior toxicity profile compared to CA significantly impacting the generation of reactive oxygen species and GSH depletion. However, this toxicity profile is unique for other CA analogs that do not contain electron‐withdrawing groups, which appear to propagate toxicity through alternative cell death mechanisms. Information generated from this study will help to inform future pharmacologic studies in animal and human models as these agents are further evaluated as potential aids for smoking cessation therapy. Support or Funding Information This work was supported by the Pacific University Research Incentive Grant Program This abstract is from the Experimental Biology 2019 Meeting. There is no full text article associated with this abstract published in The FASEB Journal .


  • Forecasting academic success through implementation of an online prerequisite review tutorials program for first year pharmacy students

    by Brendan D. Stamper, Amber V. Buhler, John P. Harrelson, Sigrid C. Roberts, Ashim Malhotra, Fawzy A. Elbarbry, Deepa Rao, Reza Karimi, R. Brigg Turner, Catherine Marlow, et al.


  • Inactivation of CYP2A6 by the Dietary Phenylpropanoid trans-Cinnamic Aldehyde (Cinnamaldehyde) and Estimation of Interactions with Nicotine and Letrozole

    by Jeannine Chan, Tyler Oshiro, Sarah Thomas, Allyson Higa, Stephen Black, Aleksandar Todorovic, Fawzy Elbarbry, John P. Harrelson

    Human exposure to trans-cinnamic aldehyde [t-CA; cinnamaldehyde; cinnamal; (E)-3-phenylprop-2-enal] is common through diet and through the use of cinnamon powder for diabetes and to provide flavor and scent in commercial products. We evaluated the likelihood of t-CA to influence metabolism by inhibition of P450 enzymes. IC50 values from recombinant enzymes indicated that an interaction is most probable for CYP2A6 (IC50 = 6.1 µM). t-CA was 10.5-fold more selective for human CYP2A6 than for CYP2E1; IC50 values for P450s 1A2, 2B6, 2C9, 2C19, 2D6, and 3A4 were 15.8-fold higher or more. t-CA is a type I ligand for CYP2A6 (KS = 14.9 µM). Inhibition of CYP2A6 by t-CA was metabolism-dependent; inhibition required NADPH and increased with time. Glutathione lessened the extent of inhibition modestly and statistically significantly. The carbon monoxide binding spectrum was dramatically diminished after exposure to NADPH and t-CA, suggesting degradation of the heme or CYP2A6 apoprotein. Using a static model and mechanism-based inhibition parameters (KI = 18.0 µM; kinact = 0.056 minute−1), changes in the area under the concentration-time curve (AUC) for nicotine and letrozole were predicted in the presence of t-CA (0.1 and 1 µM). The AUC fold-change ranged from 1.1 to 3.6. In summary, t-CA is a potential source of pharmacokinetic variability for CYP2A6 substrates due to metabolism-dependent inhibition, especially in scenarios when exposure to t-CA is elevated due to high dietary exposure, or when cinnamon is used as a treatment of specific disease states (e.g., diabetes).


  • Covalent Modification and Time-Dependent Inhibition of Human CYP2E1 by the meta-Isomer of Acetaminophen

    by John P. Harrelson, Brendan D. Stamper, John D. Chapman, David R. Goodlett, Sidney D. Nelson

    The hypothesis that N-acetyl-m-aminophenol (AMAP), the meta isomer of acetaminophen, will covalently bind to and inhibit human CYP2E1 in a time- and NADPH-dependent manner was investigated. Liquid chromatography/electrospray ionization-mass spectrometry analysis indicated that AMAP metabolites (i.e., AMAP*) selectively and covalently modified CYP2E1 apoprotein in a ratio of 1.4:1 (AMAP*/CYP2E1) in a reconstituted system. The deconvoluted spectra of CYP2E1 apoprotein from incubations containing NADPH and AMAP displayed mass shifts of 167.2 ± 7.1 and 334.4 ± 6.5 Da, suggesting the addition of one and two hydroxylated AMAP metabolites to CYP2E1, respectively. Mass shifts in cytochrome P450 reductase, cytochrome b5, and heme from these samples were not observed. CYP2E1 inhibition by AMAP increased with time in the presence of NADPH; a reversible inhibition component was also observed. The results support a bioactivation process that involves formation of a hydroquinone metabolite that undergoes further oxidation to a quinone, which reacts with CYP2E1 nucleophilic residues. The data are consistent with evidence from previous studies that identified hydroxylated AMAP glutathione conjugates collected from mice and indicate that cysteine residues are the most likely sites for adduct formation. This study reports the first direct evidence of AMAP-derived hydroquinone metabolites bound to human CYP2E1.


  • Multiple-Ligand Binding in CYP2A6: Probing Mechanisms of Cytochrome P450 Cooperativity by Assessing Substrate Dynamics

    by John P. Harrelson, William M. Atkins, Sidney D. Nelson

    The contribution of ligand dynamics to CYP allosterism has not been considered in detail. On the basis of a previous study, we hypothesized that CYP2A6 and CYP2E1 accommodate multiple xylene ligands. As a result, the intramolecular (kH/kD)obs values observed for some xylene isomers are expected to be dependent on ligand concentration with contributions from [CYP·xylene] and [CYP·xylene·xylene], etc. To explore this possibility and the utility of kinetic isotope effects in characterizing allosteric CYP behavior, steady state kinetics, product ratios, and (kH/kD)obs values for CYP2E1 and CYP2A6 oxidation of m-xylene-α-2H3 and p-xylene-α-2H3 were determined. Evidence is presented that CYP2A6 accommodates multiple ligands and that intramolecular isotope effect experiments can provide insight into the mechanisms of multiple-ligand binding. CYP2A6 exhibited cooperative kinetics for m-xylene-α-2H3 oxidation and a concentration-dependent decrease in the m-methylbenzylalcohol:2,4-dimethylphenol product ratio (9.8 ± 0.1 and 4.8 ± 0.3 at 2.5 µM and 1 mM, respectively). Heterotropic effects were observed as well, as incubations containing both 15 µM m-xylene-α-2H3 and 200 µM p-xylene resulted in further reduction of the product ratio (2.4 ± 0.2). When p-xylene (60 µM) was replaced with deuterium-labeled d6-p-xylene (60 µM), an intermolecular competitive inverse isotope effect on 2,4-dimethylphenol formation [(kH/kD)obs = 0.49] was observed, indicating that p-xylene exerts heterotropic effects by residing in the active site simultaneously with m-xylene. The data indicate that there is a concentration-dependent decrease in the reorientation rate of m-xylene, as no increase in (kH/kD)obs was observed in the presence of an increased level of metabolic switching. That is, the accommodation of a second xylene molecule in the active site leads to a decrease in substrate dynamics.


  • A comparison of substrate dynamics in human CYP2E1 and CYP2A6

    by John P. Harrelson, Kirk R. Henne, Darwin O.V. Alonso, Sidney D. Nelson